#ASH22: ALX On­col­o­gy re­ports com­plete re­sponse with an­ti-CD47 can­di­date in com­bo tri­al

NEW OR­LEANS — ALX On­col­o­gy said it’s get­ting some promis­ing, if very ear­ly, sig­nals from a small tri­al that could give its CD47 drug new life.

The biotech re­leased da­ta from a Phase I dose-es­ca­la­tion study Mon­day, show­ing that three pa­tients with new­ly di­ag­nosed acute myeloid leukemia (AML) all saw a pos­i­tive re­sponse to a com­bi­na­tion ther­a­py that in­clud­ed evor­pacept, ALX’s CD47-tar­get­ing can­di­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER